<DOC>
	<DOCNO>NCT02855359</DOCNO>
	<brief_summary>This Phase 2 study evaluate combination denintuzumab mafodotin combination RCHOP RCHP compare RCHOP alone front-line therapy patient diffuse large B-cell lymphoma follicular lymphoma Grade 3b .</brief_summary>
	<brief_title>Denintuzumab Mafodotin ( SGN-CD19A ) Combined With RCHOP RCHP Versus RCHOP Alone Diffuse Large B-Cell Lymphoma Follicular Lymphoma</brief_title>
	<detailed_description>In Part A study , patient randomize 1:1 receive denintuzumab mafodotin plus RCHOP ( rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone ) denintuzumab mafodotin plus RCHP ( rituximab , cyclophosphamide , doxorubicin , prednisone ) ass safety 2 combination regimen . Part B study design evaluate antitumor activity safety denintuzumab mafodotin combination either RCHOP RCHP ( Experimental Arm ) compare RCHOP alone ( Comparator Arm ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antineoplastic Agents , Alkylating</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Treatmentnaive patient histologically confirmed systemic de novo transform diffuse large Bcell lymphoma ( DLBCL ) ( follicular marginal zone lymphoma ) , follicular lymphoma ( FL ) Grade 3b ; patient must high intermediate high risk disease Tumor tissue available recent biopsy determine cell origin Fluorodeoxyglucoseavid disease positron emission tomography measurable disease great 1.5cm diameter Eastern Cooperative Oncology Group performance status â‰¤2 Age 18 year old Adequate study baseline laboratory parameter Previous history treat indolent lymphoma History another primary invasive cancer , hematologic malignancy , myelodysplastic syndrome remission least 3 year History progressive multifocal leukoencephalopathy Cerebral/meningeal disease relate underlying malignancy Patients follow ocular condition : corneal disorder , monocular vision ( ie . best correct visual acuity great equal 20/200 one eye ) , active ocular disorder require treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>SGN-19A</keyword>
	<keyword>Denintuzumab Mafodotin</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens , CD19</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoma , B-Cell</keyword>
	<keyword>Lymphoma , Large B-Cell , Diffuse</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Monomethyl auristatin F</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Transformed Lymphoma / DLBCL</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Liposomal doxorubicin</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Alkylating Agents</keyword>
	<keyword>Anti-Inflammatory Agents</keyword>
	<keyword>Antibiotic , Antineoplastic</keyword>
	<keyword>Antimitotic Agents</keyword>
	<keyword>Antineoplastic Agents , Alkylating</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Phytogenic Antirheumatic Agents</keyword>
	<keyword>Glucocorticoids</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Follicular Lymphoma Grade 3b</keyword>
	<keyword>immunosuppressive agent</keyword>
</DOC>